PCSK9 in diabetic kidney disease.

  title={PCSK9 in diabetic kidney disease.},
  author={Usama Elewa and Beatriz Fern{\'a}ndez-Fern{\'a}ndez and Ignacio Mah{\'i}llo-Fern{\'a}ndez and Catalina Mart{\'i}n-Cleary and Ana Bel{\'e}n Sanz and Maria Dolores Sanchez-Ni{\~n}o and Alberto Ortiz},
  journal={European journal of clinical investigation},
  volume={46 9},
BACKGROUND Chronic Kidney Disease (CKD) and, specifically, diabetic kidney disease (DKD)+, is among the fastest increasing causes of death worldwide. A better understanding of the factors contributing to the high mortality may help design novel monitoring and therapeutic approaches, since protection offered by statins in CKD patients is not satisfactory. Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) promotes hypercholesterolemia and may be targeted therapeutically. Adding anti-PCSK9… CONTINUE READING